Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT: 2009-2024

Historic EBT for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $23.2 million.

  • Gyre Therapeutics' EBT rose 94.12% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 119.62%. This contributed to the annual value of $23.2 million for FY2024, which is 130.17% up from last year.
  • Per Gyre Therapeutics' latest filing, its EBT stood at $23.2 million for FY2024, which was up 130.17% from -$77.0 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' EBT registered a high of $23.2 million during FY2024, and its lowest value of -$87.9 million during FY2021.
  • In the last 3 years, Gyre Therapeutics' EBT had a median value of $9.4 million in 2022 and averaged -$14.8 million.
  • Its EBT has fluctuated over the past 5 years, first slumped by 917.73% in 2023, then soared by 130.17% in 2024.
  • Gyre Therapeutics' EBT (Yearly) stood at -$56.3 million in 2020, then plummeted by 56.10% to -$87.9 million in 2021, then spiked by 110.70% to $9.4 million in 2022, then slumped by 917.73% to -$77.0 million in 2023, then surged by 130.17% to $23.2 million in 2024.